Benjamin Edwards Inc. Increases Holdings in Eli Lilly and Company $LLY

Posted by Brian Himes on May 6th, 2026

Eli Lilly and Company logo Benjamin Edwards Inc. increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.2% in the 4th quarter, HoldingsChannel reports. The fund owned 24,305 shares of the company’s stock after acquiring an additional 530 shares during the period. Benjamin Edwards Inc.’s holdings in Eli Lilly and Company were worth $26,129,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its position in Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. 10Elms LLP raised its stake in shares of Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the period. Miller Global Investments LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth about $33,000. Finally, Hopwood Financial Services Inc. grew its holdings in Eli Lilly and Company by 113.6% during the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock valued at $36,000 after purchasing an additional 25 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 2.2%

Shares of NYSE LLY opened at $989.02 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a market capitalization of $931.40 billion, a price-to-earnings ratio of 35.13, a PEG ratio of 1.07 and a beta of 0.48. The stock has a 50 day moving average price of $946.66 and a 200 day moving average price of $988.51. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period last year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.39 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on LLY shares. Jefferies Financial Group set a $1,300.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a research report on Friday, March 13th. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 11th. The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a “buy” rating in a report on Friday, May 1st. Guggenheim reiterated a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a research note on Tuesday. Finally, Bank of America decreased their target price on Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,217.59.

Read Our Latest Analysis on LLY

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Strong fundamentals: Q1 results and revenue beat underscore momentum in GLP‑1 franchise (Mounjaro/Foundayo) and underpin raised guidance. Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report
Positive Sentiment: Foundayo commercial launch is off to a fast start — broad pharmacy access and payer coverage are driving new prescribers and patient uptake, supporting near‑term sales growth for Lilly. Lilly’s Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Positive Sentiment: Durable clinical readthrough: New long‑term data show Omvoh (mirikizumab) maintained disease clearance in ulcerative colitis at four years — a meaningful validation for Lilly’s immunology portfolio and future revenue stability. Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
Positive Sentiment: Wall Street backing: Multiple firms have raised price targets and reiterated outperform/buy ratings (examples include Barclays and Wolfe Research), which supports investor sentiment and provides upside catalysts. Barclays/Wolfe coverage and price target updates
Neutral Sentiment: Dividend: Lilly declared a $1.73 quarterly dividend (payable June 10), a modest yield that is shareholder‑friendly but not a major valuation driver. Lilly declares second-quarter 2026 dividend
Negative Sentiment: Safety headwind: The FDA has logged serious liver events in patients taking Foundayo, which sparked a short‑term share dip and ongoing safety monitoring risk that could slow uptake or trigger label/payer scrutiny. FDA Reports Liver Failure in Patient Taking Lilly’s Foundayo
Negative Sentiment: Competitive/pricing pressure: Novo Nordisk’s oral pill momentum and talk of a price war raise margin and market‑share risk for all GLP‑1 players, keeping pricing dynamics a key watch item for Lilly. Novo Nordisk Faces Price War as Weight-Loss Pill Demand Rises

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.